# Anti-XRCC3 [XRCC3 10F1/6] mAb

Catalogue number: 151256 Sub-type: Primary antibody Images:

# Contributor

**Inventor:** Stephen West Institute: Cancer Research UK, London Research Institute: Clare Hall Laboratories Images:

# **Tool details**

#### **\*FOR RESEARCH USE ONLY**

Cancer Tools.org Name: Anti-XRCC3 [XRCC3 10F1/6] mAb

#### Alternate name:

**Class:** Monoclonal

Conjugate: Unconjugated

Description: X-Ray Repair Cross Complementing 3 (XRCC3) is a RAD51 paralog. RAD51 is a eukaryotic homologue of E. coli RecA, a recombinase, and a component of the homologous recombination DNA repair pathway. RAD51 forms a nucleoprotein filament (through binding RAD52 and single stranded DNA that are exposed following double strand breaks) that initiates recombination. XRCC3 is also a component of the homologous recombination pathway.

Purpose: Parental cell: **Organism: Tissue:** Model: Gender: Isotype: IgG1 Reactivity: Human Selectivity: Host: Mouse Immunogen: His-tagged human XRCC3 Immunogen UNIPROT ID: Sequence: Growth properties: Production details: Formulation: **Recommended controls:** 

HeLa nuclear extracts. **Bacterial resistance:** Selectable markers: Additional notes:

# **Target details**

Target: XRCC3

#### **Target alternate names:**

Target background: X-Ray Repair Cross Complementing 3 (XRCC3) is a RAD51 paralog. RAD51 is a eukaryotic homologue of E. coli RecA, a recombinase, and a component of the homologous recombination DNA repair pathway. RAD51 forms a nucleoprotein filament (through binding RAD52 and single stranded DNA that are exposed following double strand breaks) that initiates recombination. XRCC3 is also a component of the homologous recombination pathway.

Molecular weight: 37.8 kDa Cancer Tools.org

Ic50:

# **Applications**

Application: IHC ; WB **Application notes:** 

# Handling

Format: Liquid Concentration: 0.94 mg/ml Passage number: Growth medium: **Temperature:** Atmosphere: Volume: Storage medium: Storage buffer: PBS with 0.02% azide Storage conditions: -15° C to -25° C Shipping conditions: Shipping at 4° C

# Related tools

**Related tools:** 

### References

**References:** Gee et al. 2009. J Pathol. 217(1):32-41. PMID: 18825690. ; Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival. ; Eloranta et al. 2002. J Biol Chem. 277(34):30798-804. PMID: 12072434. ; Transcription factor AP-2 interacts with the SUMO-conjugating enzyme UBC9 and is sumolated in vivo.

Cancer Tools.org